Academic literature on the topic 'Ying yong cheng xu'

Abstract Introduction: Extensive-stage small cell lung cancer (ES-SCLC) is associated with limited treatment options and poor prognosis. Immunotherapy has recently showed robust clinical activity in ES-SCLC. In this double-blind, phase 3 trial, we evaluated adebrelimab (SHR-1316), a novel anti-PD-L1 antibody, in combination with standard chemotherapy (chemo) as first-line treatment for ES-SCLC. Methods: Patients naïve to systemic treatment for ES-SCLC were randomized 1:1 to receive 4-6 cycles of adebrelimab (20 mg/kg, iv, d1, q3w) or placebo with carboplatin (AUC 5, d1, q3w) plus etoposide (100 mg/m2, d1, d2, d3, q3w), followed by maintenance therapy with adebrelimab or placebo. The primary endpoint was overall survival (OS). Results: 462 patients were randomized and treated (adebrelimab+chemo, n=230; placebo+chemo, n=232). As of Oct 08, 2021, with an median follow-up of 13.5 mo (all patients; 22.5 mo for patients alive), OS was significantly prolonged with adebrelimab+chemo vs placebo+chemo (median, 15.3 mo [95% CI 13.2-17.5] vs 12.8 mo [95% CI 11.3-13.7]; hazard ratio [HR], 0.72 [95% CI 0.58-0.90], 1-sided p=0.0017); OS rate was 62.9% vs 52.0% at 12 mo and 31.3% vs 17.2% at 24 mo. Progression-free survival (PFS) per independent review committee (IRC) was 5.8 mo (95% CI 5.6-6.9) with adebrelimab+chemo vs 5.6 mo (95% CI 5.5-5.7) with placebo+chemo (HR 0.67, 95% CI 0.54-0.83); PFS rate was 49.4% vs 37.3% at 6 mo and 19.7% vs 5.9% at 12 mo. Objective response rate (ORR) and duration of response (DoR) also favored the adebrelimab+chemo group (Table 1). Grade ≥3 treatment-related adverse events occurred in 85.7% vs 84.9% of patients with adebrelimab+chemo vs placebo+chemo, with the most common (frequency ≥5%) being hematological toxicities in both groups. Conclusions: The addition of adebrelimab to chemotherapy significantly improved OS with an acceptable safety profile, supporting this combination as a new first-line treatment option for ES-SCLC. Efficacy outcomes Adebrelimab+Chemo (n=230) Placebo+Chemo (n=232) Median OS (95% CI), mo 15.3 (13.2-17.5) 12.8 (11.3-13.7) HR (95% CI)*, 1-sided log-rank p 0.72 (0.58-0.90); p=0.0017 12-mo OS rate (95% CI), % 62.9 (56.3-68.8) 52.0 (45.4-58.2) 24-mo OS rate (95% CI), % 31.3 (24.9-37.9) 17.2 (12.1-23.0) Median PFS (95% CI), mo 5.8 (5.6-6.9) 5.6 (5.5-5.7) HR (95% CI)*, 1-sided log-rank p 0.67 (0.54-0.83); p <0.0001 6-mo PFS rate (95% CI), % 49.4 (42.4-56.0) 37.3 (30.7-43.9) 12-mo PFS rate (95% CI), % 19.7 (14.5-25.5) 5.9 (3.1-10.1) IRC-assessed ORR (95% CI), % 70.4 (64.1-76.3) 65.9 (59.5-72.0) Median DoR (95% CI), mo 5.6 (4.6-6.7) 4.6 (4.3-5.5) *Stratified Cox proportional-hazards model Citation Format: Ying Cheng, Jie Wang, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, Xingxiang Xu, Xingya Li, Fei Xu, Yong Fang, Runxiang Yang, Guohua Yu, Youling Gong, Jun Zhao, Yun Fan, Quan Liu, Lejie Cao, Yu Yao, Yunpeng Liu, Xiaoling Li, Jingxun Wu, Zhiyong He, Kaihua Lu, Liyan Jiang, Huiqing Yu, Chengping Hu, Wenhua Zhao, Jian Zhao, Gang Wu, Dingzhi Huang, Chengshui Chen, Cuimin Ding, Baihong Zhang, Xiuwen Wang, Hui Luo, Baolan Li, Ben Zhang, Haowen Li, Ke Ma. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT038.

The article entitled “Aberrant Sialylation in Cancer Pathology and Metastasis, a Putative Drug Target Candidate”, by Lu D.Y., Lu T.R., Xu B., Varki A., Huang M., Zhu H., Shen Y., Yarla N.S., has been retracted on the request of the co-authors Dr. Ajit Varki, Ming Huang, Hong Zhu and Ying Shen available at: Anticancer Agents Med Chem. 2018; 18(14): 1952-1961. http://www.eurekaselect.com/165282. <P> The Corresponding Author Dr. Da-Yong Lu has included the name of the co-author Dr. Ajit Varki, Dr. Nagendra Yarla, Ming Huang, Hong Zhu and Ying Shen without their consent and the manuscript has been published in the journal Anti-Cancer Agents in Medicinal Chemistry (ACAMC). Kindly see Bentham Science Policy on Article retraction at the link given below: <P> https://benthamscience.com/journals/anti-cancer-agents-in-medicinal-chemistry/editorial-policies/). <P> Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.

The article entitled “Human Suicide, Modern Diagnosis Assistance and Magic Bullet Discovery”, by Da-Yong Lu, Peng-Peng Zhu, Hong-Ying Wu, Nagendra Sastry Yarla, Bin Xu, Jian Ding, Ajit Varki and Ting-Ren Lu, has been retracted on the request of one co-authors, Dr. Ajit Varki and Dr. Nagendra Sastry Yarla available at: Cent Nerv Syst Agents Med Chem 2019; 19(1): 15-23. http://www.eurekaselect.com/169003/article. The Corresponding Author Dr. Da-Yong Lu has included the names of the co-authors, Dr. Ajit Varki and Dr. Nagendra Sastry Yarla without their consent and the manuscript has been published in the journal, Central Nervous System Agents in Medicinal Chemistry (CNSAMC). Kindly see Bentham Science Policy on Article retraction at the link given below: (https://benthamscience.com/journals/central-nervous-system-agents-in-medicinal-chemistry/author-guidelines/) Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such, this article represents a severe abuse of the scientific publishing sys-tem. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.

Abstract Background: Pyrotinib (an irreversible tyrosine kinase inhibitor targeting EGFR, HER2 and HER4) plus capecitabine significantly improved progression-free survival (PFS) compared with that for lapatinib plus capecitabine in women with HER2-positive metastatic breast cancer after treatment with trastuzumab and taxanes in the interim analysis of the PHOEBE trial (NCT03080805; Xu et al. Lancet Oncology, 2021). In this report, we present an updated analysis of the overall survival data from this trial. Methods: This PHOEBE trial enrolled patients with HER2-positive metastatic breast cancer who had received prior trastuzumab and taxanes and up to two prior lines of chemotherapy for metastatic disease. Patients were randomly assigned (1:1) to receive either oral pyrotinib 400 mg or lapatinib 1250 mg once daily, combined with oral capecitabine 1000 mg/m² twice daily on days 1-14 of each 21-day cycle. Stratification factors were hormone receptor status (estrogen receptor [ER]- and/or progesterone receptor [PR]-positive vs. ER- and PR-negative) and previous lines of chemotherapy for metastatic disease (≤1 vs 2). The primary endpoint was PFS assessed by masked independent central review. Data cutoff for the updated overall survival analysis was March 31, 2021. Results: Between July 31, 2017 and October 30, 2018, 267 eligible patients were enrolled and randomized to either pyrotinib plus capecitabine (pyrotinib group) or lapatinib plus capecitabine (lapatinib group). 134 patients in pyrotinib group and 132 in lapatinib group started the assigned treatment. At data cutoff, the median follow-up duration was 33.2 months (95% CI 31.4-34.2) in the pyrotinib group and 31.8 months (95% CI 31.2-34.1) in the lapatinib group. 78 (58.2%) patients in the pyrotinib group and 98 (74.2%) patients in the lapatinib group received post-discontinuation therapy, with trastuzumab (60 [44.8%] in the pyrotinib group and 65 [49.2%] in the lapatinib group) being the most common. As of data cutoff date, 54 (40.3%) of 134 patients randomly assigned to the pyrotinib group and 69 (52.3%) of the 132 patients randomly assigned to lapatinib group had died. Median OS was not reached (95% CI 34.0-not reached) in the pyrotinib group and 26.9 months (22.4-not reached) in the lapatinib group (HR 0.69 [95% CI 0.48-0.98]; P=0.019). Kaplan-Meier estimated OS at 24 months was 66.6% (95% CI 57.7-74.0) and 58.8% (95% CI 49.7-66.7), respectively. 99 (73.9%) patients in the pyrotinib group and 121 (91.7%) in the lapatinib group had disease progression or had died. Pyrotinib plus capecitabine significantly improved PFS assessed by investigator compared with that for lapatinib plus capecitabine (12.5 months [95% CI 9.8-13.8] vs 5.6 months [95% CI 5.5-7.0]; HR 0.48 [95% CI 0.37-0.63]; P&lt;0.0001). The benefits of pyrotinib plus capecitabine were observed in most clinically relevant subgroups for the updated analysis of both OS and PFS (Table 1). Conclusion: With extended follow-up, pyrotinib plus capecitabine demonstrated statistically significant OS improvement compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer after trastuzumab and chemotherapy. This updated analysis of overall survival in the PHOEBE trial reaffirmed pyrotinib plus capecitabine as an established treatment option in this patient population. Table 1.Subgroup analysis of OS and PFS per investigator.HR for OSHR for PFSAll Patients0.69 (0.48-0.98)0.48 (0.37-0.63)Trastuzumab therapy for metastatic disease&lt;3 months0.67 (0.33-1.35)0.34 (0.17-0.69)3-6 months0.78 (0.34-1.76)0.66 (0.32-1.34)≥3 months0.79 (0.37-1.66)0.44 (0.26-0.75)Trastuzumab resistanceNo0.60 (0.39-0.91)0.44 (0.32-0.61)Yes0.94 (0.48-1.85)0.58 (0.35-0.98)HER2 amplification by FISH0.76 (0.39-1.51)0.57 (0.35-0.92)Pathological gradingII0.65 (0.33-1.28)0.51 (0.31-0.85)III0.82 (0.41-1.65)0.51 (0.31-0.83)Unknown0.70 (0.41-1.21)0.45 (0.29-0.70)Visceral lesionsVisceral0.59 (0.40-0.88)0.45 (0.33-0.62)Non-visceral1.28 (0.55-2.95)0.57 (0.31-1.04)ECOG performance status00.72 (0.40-1.29)0.42 (0.26-0.66)10.67 (0.43-1.04)0.50 (0.36-0.71)Estrogen and progesterone receptor statusPositive0.74 (0.44-1.25)0.58 (0.39-0.86)Negative0.64 (0.39-1.04)0.41 (0.28-0.60)Previous lines of chemotherapy for metastatic disease00.72 (0.38-1.35)0.47 (0.30-0.74)10.73 (0.44-1.22)0.49 (0.32-0.73)20.56 (0.24-1.32)0.56 (0.28-1.08)Data are median (95% CI). HRs are from unstratified analyses. Citation Format: Binghe Xu, Min Yan, Fei Ma, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun Zou. Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS3-02.

Abstract Background Entinostat is a novel, potent, once weekly, orally bioavailable, class I selective histone deacetylase (HDAC) inhibitor. In a previous Phase II study, the combination of entinostat with exemestane showed significant improvement of overall survival in patients with advanced hormone receptor (HR) positive breast cancer. To verify and further confirm the benefit of HDAC inhibitor in combination with exemestane we designed a randomized, controlled trial to assess the efficacy and safety in a larger population of Chinese patients with advanced, HR positive breast cancer. Methods We carried out the randomized, double-blind, placebo-controlled, Phase III trial at 35 sites in China. Eligible patients were women (aged ≥18 years) with HR positive, human epidermal growth factor receptor-2 (HER2) negative breast cancer, whose disease had relapsed or progressed after at least one endocrine therapy (either in advanced or metastatic or adjuvant setting), and who had at least one measurable lesion, adequate organ function, ECOG performance status of 0-1, and adequate haematological and biochemical parameters. Patients were randomly assigned (2:1) via an interactive web-response system to orally take 5 mg entinostat or placebo. Both groups received oral administration of 25 mg exemestane daily. Randomization was stratified according to previous usage of CDK4/6 (yes vs no), fulvestrant (yes vs no), chemotherapy (yes vs no), and the presence of visceral metastases (yes vs no). Patients, investigators, study site staff, and the sponsor were masked to treatment assignment. The primary endpoint was Independent Radiographic Committee (IRC)-assessed progression free survival (PFS). Efficacy and safety analyses were done in all patients who received at least one dose of any study treatment. The study has reached the required number of events for final analysis of the primary endpoint. The trial is no longer enrolling patients, but follow-up for investigation of overall survival is ongoing. This study was registered with ClinicalTrials.gov with the number of NCT03538171. Results From April 16th, 2019 to May 13th, 2020, 354 patients were enrolled and randomly assigned as 235 to the entinostat group and 119 to the placebo group. IRC-assessed median PFS was 6.32 months (95% CI 5.30-9.11) in the entinostat group and 3.72 months (95% CI 1.91-5.49) in the placebo group (HR 0.74 [95% CI 0.57-0.96]; p&lt;0.001). The most common Grade 3 or 4 adverse events in the entinostat group vs placebo group were neutropenia (103 [43.8%] vs 119 [0.8%] ), thrombocytopenia (20 [8.5%] vs 1 [0.8%]), and leucopenia (15 [6.4%] vs 0). Serious adverse events occurred in 28 out of 235 patients (11.9%) in the entinostat group and 11 out of 119 patients (9.2%) in the placebo group. Conclusions Entinostat and exemestane combination treatment significantly improved PFS compared with exemestane alone in patients with advanced, HR positive, HER2 negative breast cancer that progressed after previous endocrine therapy. Entinostat and exemestane combination was generally tolerated and can offer meaningful clinical benefit in these patients with unmet medical need. This phase III trial was sponsored by Taizhou EOC Pharma Co., Ltd. Citation Format: Binghe Xu, Qingyuan Zhang, Xichun Hu, Qing Li, Tao Sun, Wei Li, Quchang Ouyang, Jingfen Wang, Zhongsheng Tong, Min Yan, Huiping Li, Xiaohua Zeng, Changping Shan, Xian Wang, Xi Yan, Jian Zhang, Yue Zhang, Jiani Wang, Liang Zhang, Ying Lin, Jifeng Feng, Qianjun Chen, Jian Huang, Yongkui Lu, Hongsheng Li, Jinsheng Wu, Jing Cheng, Yanrong Hao, Cuizhi Geng, Min Lu, Yanping Li, Xi Chen, Lihua Song, Xueying Wu, Changlu Hu, Xinhong Wu, Xiaojia Wang, Yueyin Pan, Yuehong Cui, Guohua Yu, Sanyuan Sun. A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS1-06.

The growing demand for higher energy density batteries is increasing due to needs of electric vehicle (EV) [1]. Until now, it cannot exceed the one-time charging distance of an internal combustion engine vehicle, due to energy limit of batteries. Li metal anode (LMA) is one of the attractive anode candidates because of the lowest electrochemical redox electrode potential (-3.04 V vs. SHE) and the extremely high theoretical gravimetric capacity (3,860 mAh g-1) compared to graphite anode (372 mAh g-1) [2]. However, uneven Li deposition causes dendritic growth leading to low Coulombic efficiency (CE) and safety hazards which is impeding the practical use of LMAs [3]. Recently, to suppress such dendritic growth, various solutions such as introduction of solid-state electrolyte (SSE) [4], artificial solid electrolyte interphase (ASEI) [5], 3D current collector (CC) [6], and lithiophilic materials [7] have been proposed. Among the several approaches, introducing lithiophilic material on a CC is one of the facile and effective strategies to increase the lithiophilicity, and hence to induce the planar growth of Li. Also, assuming that electroplating is largely divided into two steps: nucleation and growth, lithiophilic material can change the intrinsic nucleation behavior by preferentially forming a different phases such as Li alloys [8]. Since the Li nucleation process significantly influences the final growth of Li, different cycling behaviors of LMAs would be expected depending on lithiophilic material [9]. As for the methods to adopt the lithiophilic materials, the electrodeposition is very attractive, since it can easily control the surface morphology, which might affect the Li deposition morphology and the related behavior. In this regard, we chose the tin (Sn) as a lithiophilic material, which can be deposited on Cu CC by electroplating, and moreover have a fast Li ion diffusion coefficient [10]. Specifically, in this work, we study the effect of surface morphology of lithiophilic Sn deposited on copper CC by testing Li deposition/stripping behavior for a LMAs. For different morphology, a direct current electrodeposition (DC) and pulsed electrodeposition (PED) were used. Fig.1 is FE-SEM images of Cu@Sn with DC growth and PED growth. Fig.1 (a) shows Sn particles are growing without filling the pores. However, Fig.1 (c) shows Sn particles are growing with filling the pores. At Fig.1 (b) and (d), the morphology difference is conspicuous between DC and PED growth. Fig.1 (b) presents island growth in which nuclei grow on existing nuclei because there is only Ton without relaxation time. While, Fig.1 (d) shows that after rearrangement of deposited atom at Toff, new nucleation sites are created by continuously applying pulses, thereby obtaining the coalescence growth. At Fig.2, Cu@Sn (PED) shows the longer cycle life than bare Cu and Cu@Sn (DC) because Cu@Sn (PED) has an uniformly distributed nano Sn morphology, which provides more sites for Li nucleation to prevent dendritic growth. References [1] PARAJULY, Keshav; TERNALD, Daniel; KUEHR, Ruediger. The Future of Electric Vehicles and Material Resources: A Foresight Brief. 2020. [2] XU, Wu, et al. Lithium metal anodes for rechargeable batteries. Energy & Environmental Science, 2014, 7.2: 513-537. [3] CHENG, Xin-Bing, et al. Toward safe lithium metal anode in rechargeable batteries: a review. Chemical reviews, 2017, 117.15: 10403-10473. [4] YU, Seungho, et al. Elastic properties of the solid electrolyte Li7La3Zr2O12 (LLZO). Chemistry of Materials, 2016, 28.1: 197-206. [5] LI, Nian‐Wu, et al. An artificial solid electrolyte interphase layer for stable lithium metal anodes. Advanced materials, 2016, 28.9: 1853-1858. [6] YUN, Qinbai, et al. Chemical dealloying derived 3D porous current collector for Li metal anodes. Advanced Materials, 2016, 28.32: 6932-6939. [7] YAN, Kai, et al. Selective deposition and stable encapsulation of lithium through heterogeneous seeded growth. Nature Energy, 2016, 1.3: 1-8. [8] PEI, Allen, et al. Nanoscale nucleation and growth of electrodeposited lithium metal. Nano letters, 2017, 17.2: 1132-1139. [9] CHEN, Xiao-Ru, et al. Role of Lithiophilic Metal Sites in Lithium Metal Anodes. Energy & Fuels, 2021, 35.15: 12746-12752. [10] SHI, Jianjian; WANG, Zhiguo; FU, Yong Qing. Density functional theory study of diffusion of lithium in Li–Sn alloys. Journal of materials science, 2016, 51.6: 3271-3276. [11] IBL, N.; SCHADEGG, K. Surface roughness effects in the electrodeposition of copper in the limiting current range. Journal of the Electrochemical Society, 1967, 114.1: 54. Figure 1

Armido Studer of Wilhems-University Münster effected (Chem. Commun. 2012, 48, 5190) the enantioselective conjugate addition of 2 to 1, leading to the cyclopropane 3. Karl Anker Jørgensen of Aarhus University devised (J. Am. Chem. Soc. 2012, 134, 2543) a route to cyclobutanes based on the enantioselective addition of 5 to the nitroalkene 4. Jose L. Vicario of the Universidad del País Vasco reported (Angew. Chem. Int. Ed. 2012, 51, 4104) a similar procedure. Benjamin List of the Max-Planck-Institute Mülheim epoxidized (Adv. Synth. Catal. 2012, 354, 1701) cyclopentenones such as 7 with high ee. Lutz H. Gade of the Universität Heidelberg observed (J. Am. Chem. Soc. 2012, 134, 2946) high ee in the benzylation of 9. Cheng Ma of Zhejiang University formylated (J. Org. Chem. 2012, 77, 2959) cyclopentanone, then condensed the resulting aldehyde 12 with 13 to give 14. Hao Xu of Georgia State University cyclized (Org. Lett. 2012, 14, 858) 15 to the cyclopentenone 16. (+)-Rosephilin 19 inhibits several phosphatases. Bernard L. Flynn of Monash University prepared (Org. Lett. 2012, 14, 1740) the carbocyclic core of 19 by cyclizing 17 to the cyclopentenone 18. Masanori Yoshida of Hokkaido University designed (J. Org. Chem. 2011, 76, 8513) a very simple organocatalyst for the enantioselective conjugate addition of 21 to 20. Samuel H. Gellman of the University of Wisconsin showed (Org. Lett. 2012, 14, 2582) that nitromethane could be added to 23 with high ee. Hiroaki Sasai of Osaka University effected (Angew. Chem. Int. Ed. 2012, 51, 5423) the enantioselective cyclization of the prochiral 25. Ying-Chun Chen of Sichuan University found (Angew. Chem. Int. Ed. 2012, 51, 4401) that the diene 27 could be converted to 29 by way of the intermediate trienamine. Bor-Cherng Hong of the National Chung Cheng University observed (Chem. Commun. 2012, 48, 2385) that under organocatalysis, only one enantiomer of 31 would add to 30, delivering 32 in high ee. Aromatization of 32 led to (+)-galbulin 33.